Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, has acquired Thynk Health, a specialized leader in lung cancer screening and incidental findings management. Financial terms were not disclosed.
The combination unites two of healthcare’s most installed platforms in imaging-driven care coordination, with a combined footprint spanning hundreds of hospitals including five of the top ten health systems in the United States.
Together, the platforms process well over half a billion clinical reports and messages annually in real time. Azra AI’s platform supports patients from initial suspicion through treatment and survivorship, bridging gaps that traditional electronic health records and point solutions were not designed to address. Its Clinical Patient Data Layer converts fragmented clinical data into structured, actionable workflows across radiology, pathology, cardiology, emergency departments, and other service lines. Capabilities include incidental findings management, cancer patient identification, patient navigation and care coordination, registry case-finding, tumor board coordination, clinical trial matching, and real-time reporting and analytics.
Thynk Health deepens that foundation in the critical window between an imaging finding and a confirmed diagnosis, the moment where follow-up delays most often translate into later-stage disease and worse outcomes. Health systems already using Thynk will now have access to Azra AI’s full platform, while existing Azra clients gain strengthened lung cancer screening and incidental findings capabilities.
John Marshall will continue as CEO of the combined organization. Daniel Weeks, formerly CEO of Thynk Health, will assume the role of Chief Operating Officer at Azra AI. Both companies will continue supporting existing customer deployments throughout the integration process with no disruption to current contracts or workflows.
KEY QUOTES:
“Health systems are moving beyond fragmented tools and toward true enterprise-wide intelligence platforms. EHRs were not built for this level of complexity, especially when it comes to delivering the specialized clinical workflows that turn a finding into a follow-up and a follow-up into a life saved. The future of care is not just managing patients once disease is suspected, it’s identifying patients earlier, often before symptoms appear. Azra was built from day one to be something fundamentally different, by leveraging discrete clinical data across the enterprise, we can surface high-risk, asymptomatic patients and accelerate diagnosis of life-threatening conditions. This combination with Thynk Health, and their amazing people and technology, accelerates our mission of saving lives every day.”
John Marshall, CEO, Azra AI
“Too many important imaging findings never lead to action, a missed follow-up, a gap in communication, and a patient’s early-stage diagnosis becomes a late-stage one. That’s the problem Thynk was built to solve. Joining Azra gives us the platform depth and reach to deliver continuous, coordinated care with highly actionable data at vast scale across entire health system populations, not just individual programs. There is simply nothing else like it on the market, one platform, one partner, one mission.”
Daniel Weeks, Chief Operating Officer, Azra AI
